ATXS

11.61

37.07% 3.14

Handel nachbörslich: 11.63 0.02 +0.17%

Astria Therapeutics Inc (ATXS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$8.47

Offen:

$11.93

24-Stunden-Volumen:

34.66M

Relative Volume:

50.58

Marktkapitalisierung:

$655.21M

Einnahmen:

Nettoeinkommen (Verlust:

$-72.89M

KGV:

-4.7975

EPS:

-2.42

Netto-Cashflow:

$-68.47M

1W Leistung:

+55.42%

1M Leistung:

+56.26%

6M Leistung:

+175.12%

1J Leistung:

+4.88%

1-Tages-Spanne:

$11.53

$12.17

1-Wochen-Bereich:

$7.595

$12.17

52-Wochen-Spanne:

$3.555

$12.52

Astria Therapeutics Inc Stock (ATXS) Company Profile

Firmenname

Astria Therapeutics Inc

Sektor

Healthcare (1140)

Branche

Biotechnology (636)

Telefon

617-349-1971

Adresse

22 BOSTON WHARF ROAD, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-11

Neueste SEC-Einreichungen

ATXS's Discussions on Twitter

Vergleichen Sie ATXS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATXS Astria Therapeutics Inc	11.61	478.00M	0	-72.89M	-68.47M	-2.42
VRTX Vertex Pharmaceuticals Inc	412.22	104.45B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	469.36	60.95B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	572.60	59.11B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	812.95	49.23B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.94	35.92B	4.56B	-176.77M	225.30M	-1.7177

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-17	Bestätigt	H.C. Wainwright	Buy
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2025-01-31	Eingeleitet	JMP Securities	Mkt Outperform
2024-07-29	Eingeleitet	TD Cowen	Buy
2023-03-28	Eingeleitet	Evercore ISI	Outperform

Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten

01:48 AM

BioCryst to Acquire Astria in $700M Deal - USA Herald

01:48 AM

01:09 AM

Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings - Benzinga

01:09 AM

12:20 PM

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga

12:20 PM

11:50 AM

BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics, Inc.. - MarketScreener

11:50 AM

11:25 AM

Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire

11:25 AM

11:21 AM

Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today - TipRanks

11:21 AM

11:17 AM

BioCryst to Acquire Astria Therapeutics in $700 Million Deal - Contract Pharma

11:17 AM

10:52 AM

BioCryst deepens rare diseases focus with $700 million deal for Astria - Reuters

10:52 AM

10:15 AM

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday - Benzinga

10:15 AM

10:03 AM

ATXS Stocks Flying High: Too Late to Buy? - StocksToTrade

10:03 AM

09:53 AM

BioCryst To Acquire Astria Therapeutics - citybiz

09:53 AM

08:29 AM

ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders - Business Wire

08:29 AM

08:07 AM

BioCryst to Acquire Astria Therapeutics for $700 Million Includi - GuruFocus

08:07 AM

08:06 AM

BioCryst Announces Acquisition of Astria Therapeutics (ATXS) at $13.00 Per Share - GuruFocus

08:06 AM

08:04 AM

BioCryst (BCRX) to Acquire Astria Therapeutics in $700M Deal - GuruFocus

08:04 AM

08:02 AM

BioCryst To Acquire Astria Therapeutics In $700M Deal - Stocktwits

08:02 AM

08:00 AM

BioCryst Pharmaceuticals To Acquire Astria Therapeutics In $700 Million Cash-and-Stock Deal - Nasdaq

08:00 AM

07:58 AM

BioCryst To Acquire Astria Therapeutics In $700 Mln Cash-and-Stock Deal - Nasdaq

07:37 AM

07:33 AM

Astria Therapeutics stock soars after BioCryst acquisition announcement, BioCryst falls By Investing.com - Investing.com Canada

07:33 AM

07:32 AM

BioCryst Announces Merger with Astria Therapeutics - TipRanks

07:32 AM

07:31 AM

BioCryst to buy Astria Therapeutics for $13 per share - MSN

07:31 AM

07:20 AM

Combining price and volume data for Astria Therapeutics Inc.July 2025 Final Week & Risk Managed Investment Signals - newser.com

07:20 AM

07:17 AM

BioCryst to acquire Astria Therapeutics, strengthening presence in HAE, transforming growth profile - MarketScreener

07:17 AM

07:04 AM

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - GlobeNewswire

07:04 AM

05:53 AM

What to do if you’re stuck in Astria Therapeutics Inc.July 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com

05:53 AM

05:34 AM

Can Astria Therapeutics Inc. stock maintain operating margins2025 Momentum Check & Fast Moving Stock Watchlists - newser.com

05:34 AM

05:11 AM

How to forecast Astria Therapeutics Inc. trends using time seriesMarket Risk Report & Real-Time Buy Signal Alerts - newser.com

05:11 AM

02:02 AM

Published on: 2025-10-14 01:02:46 - newser.com

02:02 AM

Oct 13, 2025

BioCryst Pharmaceuticals To Acquire Astria In $700 Million Deal - Finimize

Oct 13, 2025

Institutional scanner results for Astria Therapeutics Inc.2025 Technical Overview & Weekly High Return Forecasts - newser.com

Oct 13, 2025

Oct 12, 2025

Is it too late to sell Astria Therapeutics Inc.Swing Trade & Expert Verified Stock Movement Alerts - newser.com

Oct 12, 2025

Oct 11, 2025

3 Biotech Stocks That Could More Than Triple if Their Trials Succeed - MSN

Oct 11, 2025

Oct 10, 2025

Can Astria Therapeutics Inc. stock sustain institutional interest2025 Market Outlook & High Conviction Buy Zone Alerts - newser.com

Oct 10, 2025

Comparing Astria Therapeutics Inc. in custom built stock radars2025 Retail Activity & Verified Entry Point Signals - newser.com

Oct 10, 2025

Visual analytics tools that track Astria Therapeutics Inc. performanceJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com

Oct 10, 2025

Tick level data insight on Astria Therapeutics Inc. volatility2025 Winners & Losers & Technical Entry and Exit Tips - newser.com

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reaffirms Sell (D-) Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat

Oct 09, 2025

H.C. Wainwright reiterates Buy rating on Astria Therapeutics stock at $20 - Investing.com Canada

Oct 09, 2025

Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting - Business Wire

Oct 09, 2025

Analyzing Astria Therapeutics Inc. with multi timeframe chartsEarnings Risk Summary & Reliable Price Breakout Signals - newser.com

Oct 09, 2025

How to interpret RSI for Astria Therapeutics Inc. stock2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com

Oct 09, 2025

Oct 08, 2025

Astria Therapeutics begins phase 3 long-term trial for HAE treatment - Investing.com Nigeria

Oct 08, 2025

Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with - PharmiWeb.com

Oct 08, 2025

Astria Therapeutics (ATXS) Begins Phase 3 Trial for Hereditary A - GuruFocus

Oct 08, 2025

Astria Therapeutics begins phase 3 long-term trial for HAE treatment By Investing.com - Investing.com South Africa

Oct 08, 2025

Astria Therapeutics initiates the phase 3 ORBIT-EXPANSE long-term trial of navenibart in people with hereditary angioedema - MarketScreener

Oct 08, 2025

Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema - Business Wire

Oct 08, 2025